Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Viactiv Single Product Introduction Led To Future Line Success - Leiner Exec

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement companies should focus on launching single branded products instead of whole lines in order to best attract and establish consumer interest, Leiner Health Products New Products Marketing Director David Weinberg advised at the Nutrimarket conference in San Francisco March 27-28.

You may also be interested in...

Viactiv Bars, Drinks TV Ad Stresses Energy Benefits For Women

Viactiv snack bars and drinks contain energy "to go" and "nutrients a woman's body craves," Mead Johnson says in a TV commercial supporting the product line extensions.

Pharmavite, GNC Launching SAM-e Dietary Supplement For Joints/Mood

Pharmavite and General Nutrition are introducing dietary supplements containing S-adenosylmethionine, a naturally occurring compound said to improve mood and help joints stay supple. BASF supplies the compound to Pharmavite and GNC; the raw material is produced in Italy.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts